Longevity Medicine in 2026: What Actually Works, and What Is Marketing

Longevity has become the most oversold word in medicine. Clinics promise biological age reversal in numbers accurate to one decimal place; supplement brands imply decades. Underneath the noise there is a real field with real findings, and it is worth separating into three piles: what is established, what is promising, and what is being sold well ahead of its evidence.

Pile one: unglamorous and proven

The interventions with the strongest evidence for extending healthy years are the ones nobody can charge much for. Resistance training two or three times a week preserves muscle mass, which is the single best predictor of independence in later decades. Sleep of adequate duration governs metabolic and immune function more powerfully than any infusion. Blood pressure and metabolic control, not smoking, and maintaining social connection all show effect sizes that no clinic protocol can match.

Any longevity program that skips these and moves straight to an IV drip has its priorities inverted. We say so at consultation, which occasionally costs us the sale.

Pile two: promising, with real signals

Between the proven and the speculative sits a genuinely interesting middle. NAD+ declines with age, and its role in mitochondrial function and DNA repair is well described in the laboratory; clinical evidence in humans is earlier and smaller, and honest practice means saying so while still offering it to patients who understand where the science stands.

Mesenchymal cellular therapy has a strong mechanistic story around immune modulation and inflammation, with clinical trial data that is growing but still uneven across indications. The same is true of exosome-based protocols. These are legitimate interventions with legitimate uncertainty, and the appropriate way to offer them is with a written expectation of what may and may not change.

Structured screening also belongs in this pile. Bioimpedance and body composition, arterial stiffness measures, inflammatory markers, fasting insulin and HbA1c, and imaging where symptoms justify it — these turn a vague goal into a baseline you can measure against a year later.

Pile three: sold ahead of the science

Then there is the marketing layer. Biological age scores presented as precise clinical facts, when the underlying tests disagree with each other by years. Full-body plasma exchange sold to healthy people. Very high dose supplement stacks assembled from mouse data. Any claim involving a specific number of added years.

The tell is usually the certainty. Genuine longevity medicine is full of ranges and conditions; the marketing version is full of guarantees.

What a serious program looks like

• A baseline built from bloodwork and objective measurements, taken before anything is recommended
• A written plan that names what is being targeted and what success would look like
• Lifestyle prescriptions treated as core, not as a leaflet handed over at the end
• Interventions ranked by evidence, with the uncertainty stated plainly
• A repeat measurement at a defined interval — usually three to six months

The honest position

Nobody can currently promise you additional years. What a well-run program can plausibly do is improve the things you feel — energy through the afternoon, sleep quality, recovery after exertion, joint comfort, inflammatory markers on paper — and remove the modifiable risks that shorten healthy life. That is a smaller claim than the industry makes, and a more defensible one.

If you want a candid read on what a longevity program could realistically do for your situation, send your recent bloodwork to our medical team. We will tell you which of the three piles your goals fall into.